Navigation Links
Isis Scientist Awarded 2009 Ebert Prize
Date:4/6/2009

e have completed a multiple-dose Phase 1 study that provided further evidence that antisense drugs are active and well-tolerated when administered orally."

The Ebert Prize was established in 1873 by the APhA and is the oldest pharmacy award in the United States awarded annually to researchers who have reported significant results for original investigation published in the Journal of Pharmaceutical Sciences.

(1) Lloyd Tillman, Richard S. Geary, Gregory E. Hardee. Oral Delivery of Antisense Oligonucleotides in Man. Journal of Pharmaceutical Sciences. 2008; 97 (1): 225-36.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.

This press release includes forward-looking statements regarding Isis' discovery and development of antisense drugs and the potential for Isis' development of antisense drugs that can be administered orally. Any statement describing Isis' goals, expectations, financ
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
2. Scientists Probe Sepsis Deadly Secrets
3. Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
4. Scientists Develop Natural Protection for Stored Foods
5. Scientists detect presence of marburg virus in african fruit bats
6. Scientists Spot Brains Free Will Center
7. Scientists ID Likely Culprit in Popcorn Lung
8. Scientists explain how insulin secreting cells maintain their glucose sensitivity
9. Scripps Research scientists shed new light on how antibodies fight HIV
10. Scientists, physicians present latest findings in personalized cancer treatment and prevention
11. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... research team has been awarded a three-year $1.7 ... (NIH) to develop new imaging technologies and data ... how large networks of neurons in the brain ... help researchers identify the precise interactions between millions ... and speaking, and alterations in these interactions that ...
(Date:9/30/2014)... 2014 Elevate , the latest product ... in and out of the gym by providing natural ingredients ... attention of Shane Michaels, prompting an investigative review. , ... reason most people simply just don’t have the ability to ... at work, getting the motivation to finish a project, or ...
(Date:9/30/2014)... White Plains, NY (PRWEB) September 30, 2014 ... (HPCW) recently hosted its annual “In Celebration” gala, ... furthering the nonprofit’s mission of striving to provide ... individuals and families facing a serious or life-limiting ... Westchester Country Club in Rye, NY and recognized ...
(Date:9/30/2014)... 2014 Dr. Karl R.O.S. Johnson, DC, ... of care that is dramatically improving the health ... Chiropractic Neurology & Nutrition—applies a proprietary, multi-dimensional approach that ... addresses sources of inflammation, neurology of the joint and ... from the brain to the spine, to the legs, ...
(Date:9/30/2014)... WASHINGTON (Sept. 30, 2014) Levothyroxine is considered the ... and a new review of therapies for the condition ... not altered that assessment, say a team of investigators.,1Their ... journal Thyroid , finds insufficient consistent data exist ... whether generic, or sold under various trade names, such ...
Breaking Medicine News(10 mins):Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 3Health News:New guidelines for treatment of hypothyroidism endorse current therapy 2
... Plans, Lists for Third ... Straight Year, FLINT, ... Medicare Advantage and Medicaid health,plans have been recognized by U.S. News & ... named among the top 50,Commercial plans and the top 25 plans for ...
... to add 300 jobs, PITTSBURGH, Oct. 26 ... has selected Highmark Medicare Services Inc. as the ... Part A,and Part B fee-for-service claims and other ... Columbia. Highmark Medicare Services will,process Medicare fee-for-services claims ...
... Aetna Claims at No Cost -, PARSIPPANY, N.J., ... company focused on providing innovative products for,electronic health care ... its relationship with Aetna to include a direct,connection for ... a leading,diversified health care benefits company with more then ...
... to help manage performance dashboards for Military ... Healthcare Facilities worldwide, ... Military Health System (MHS), awarded a four-year, $1.3,million contract extension ... will extend a previous contract,through 2011, for implementation of SciHealth,s ...
... 25, 2007 Shire plc (LSE: SHP, NASDAQ: ... announced that data from a 12-month study of ... Disorder (ADHD) patch, demonstrated that DAYTRANA provided significant ... aged 6 to 12 years. The study ...
... outcomes, researchers say , THURSDAY, Oct. 25 (HealthDay News) ... (ANP) can lessen cardiac injuries after heart attack and boost ... Japanese study in this week,s issue of The Lancet ... heart muscle (infarct) and lessened what,s known as "reperfusion injuries," ...
Cached Medicine News:Health News:Highmark Medicare Services Awarded New Contract from Centers for Medicare & Medicaid Services 2Health News:MD On-Line Expands Relationship with Aetna for Direct Claim Submission 2Health News:SciHealth Awarded Multi-year Contract with U.S. Department of Defense, Military Health System 2Health News:Long-term 12-month safety data on ADHD patch DAYTRANA 2
(Date:9/30/2014)... ATLANTA , Sept. 30, 2014  Georgia-Pacific ... systems, towels and tissue for a wide range ... success of its product lines in healthcare, including ... practices, Georgia-Pacific Professional is introducing its healthcare products ... "Georgia-Pacific Professional understands the importance of infection control ...
(Date:9/30/2014)... 30, 2014   Decision Resources Group finds ... anemic chronic kidney disease non-dialysis (CKD-ND) patients are ... medication. In addition, one-year persistency is similar between ... Other key findings from the report entitled ... Erythropoiesis Stimulating Agents in Late Stage Chronic Kidney ...
(Date:9/30/2014)... , Sept. 30, 2014   Acutus ... minimally invasive real-time 3D Cardiac Chamber Imaging and Dipole ... and / or sustain complex cardiac arrhythmias, including atrial ... to continue developing its imaging/mapping system as well as ... will allow Acutus Medical to complete work on the ...
Breaking Medicine Technology:Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 2Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 3
... NEW YORK, Oct. 7 Reportlinker.com announces that ... its catalogue: U.S. Venous Access ... This study covers U.S. markets for ... (PICCs), central venous catheters (CVCs), dialysis catheters, implantable ...
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ), ... extracellular matrix, today announced that it will host a ... in New York. During the meeting, Halozyme,s management will ... business alliances with Roche and Baxter, and an update ...
Cached Medicine Technology:Reportlinker Adds U.S. Venous Access Catheter Market 2Reportlinker Adds U.S. Venous Access Catheter Market 3Reportlinker Adds U.S. Venous Access Catheter Market 4Halozyme Therapeutics to Host Analyst Meeting on October 14 in New York 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: